Reduced penetrance in genetic ALS/FTD spectrum disorders: implications for genetic counseling, predictive testing and treatment
- 4 July 2026
- journal article
- review article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- p. 1-12
Abstract
As the offer of genetic testing for people with ALS/FTD becomes standard of care, clinicians and affected individuals should have accurate and balanced information regarding the clinical and familial implications of test results, including the penetrance of identified variants. Published estimates of the penetrance of specific ALS/FTD variants, including the C9orf72 repeat expansion, have varied widely. However, it is now apparent that most pathogenic variants identified in clinical testing exhibit reduced penetrance. Although data on the disease risk of many variants is limited and likely to evolve in the coming years, the challenges of estimating penetrance should not preclude transparent discussion of these issues with affected individuals and their families. Here, we review published penetrance data and highlight genetic counseling considerations to support the clinician in discussing disease risk and facilitating decision-making in genetic testing and patient care.Keywords
This publication has 114 references indexed in Scilit:
- ALS Identified: two‐year findings from a sponsored ALS genetic testing programAnnals of Clinical and Translational Neurology, 2024
- GRN Mutations Are Associated with Lewy Body DementiaMovement Disorders, 2022
- Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations2021
- Unusually long duration and delayed penetrance in a family with FTD and mutation in MAPT (V337M)American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016
- Large Proportion of Amyotrophic Lateral Sclerosis Cases in Sardinia Due to a Single Founder Mutation of the TARDBP GeneArchives of Neurology, 2011
- Association of TMEM106B Gene Polymorphism With Age at Onset in Granulin Mutation Carriers and Plasma Granulin Protein LevelsArchives of Neurology, 2011
- The G389R mutation in the MAPT gene presenting as sporadic corticobasal syndromeMovement Disorders, 2008
- Progranulin null mutations in both sporadic and familial frontotemporal dementiaHuman Mutation, 2007
- Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315RAnnals of Neurology, 2003
- Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosisAnnals of Neurology, 1997